Gynecologic Oncology

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

December 01, 2021

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

Lenvatinib plus pembrolizumab displays efficacy in advanced endometrial cancer

November 18, 2021

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

Lack of health insurance directly reduces cancer screening rates, most recent and long-term

November 08, 2021

Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.

Recruitment to Phase 2 Trial Examining PDS0101 Triplet in HPV Cancers Temporarily Suspended

November 01, 2021

The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer

October 25, 2021

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Data aid in treatment for vulvovaginal health, sexual function after cancer

October 11, 2021

Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.